<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02349295</url>
  </required_header>
  <id_info>
    <org_study_id>14310</org_study_id>
    <secondary_id>I1F-MC-RHBE</secondary_id>
    <secondary_id>2011-002328-42</secondary_id>
    <nct_id>NCT02349295</nct_id>
  </id_info>
  <brief_title>A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis</brief_title>
  <acronym>SPIRIT-P2</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate how effective and safe the study drug known as
      ixekizumab is in participants with active psoriatic arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 31, 2014</start_date>
  <completion_date type="Actual">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">September 9, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20)</measure>
    <time_frame>Week 24</time_frame>
    <description>ACR20 response is defined as a greater than or equal to (≥) 20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain visual analog scale (VAS), Participant's Global Assessment of Disease Activity VAS (PatGA), Physician's Global Assessment of the Disease Activity VAS (PGA), Participant's Assessment of Physical Function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or Acute Phase Reactant as measured by high sensitivity C-reactive protein (hs-CRP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>HAQ-DI is a participant reported questionnaire that measures disease-associated disability(physical function).It consists of 24 questions with 8 domains: dressing/grooming,arising,eating,walking,hygiene,reach,grip and other daily activities. The disability section scores the participant's self-perception on degree of difficulty (0=without any difficulty,1=with some difficulty,2=with much difficulty,3=unable to do)covering the 8 domains.The HAQ-DI is a composite ranging from 0-3 with lower scores indicating less functional disability.The reported use of special aids/devices and/or the need for assistance of another person to perform these activities is assessed.Least Square (LS) mean calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment,baseline score,geographic region, TNFi experience,visit, treatment-by-visit interaction(itcn), geographic region-by-visit itcn,TNFi experience-by-visit itcn and baseline score-by-visit itcn.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR20</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 50 Index (ACR50)</measure>
    <time_frame>Week 24</time_frame>
    <description>ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 70 Index (ACR70)</measure>
    <time_frame>Week 24</time_frame>
    <description>ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI compared to their baseline measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Minimal Disease Activity (MDA)</measure>
    <time_frame>Week 24</time_frame>
    <description>It uses a composite of 7 key outcome measures (includes PASI) used in PsA to encompass all of the domains of the disease to measure the overall state of a patients' disease. The LEI is used to assess tender entheseal points. Patients are classified as achieving MDA if they fulfill 5 of 7 outcome measures: 1. TJC ≤1, 2. SJC ≤1, 3. PASI total score ≤1 or BSA ≤3, 4. patient pain VAS score of ≤15, 5. patient global VAS score of ≤20, 6. HAQ-DI score ≤0.5, 7. tender entheseal points (6 entheseal points) ≤1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Complete Resolution in Enthesitis as Assessed by the Leeds Enthesitis Index (LEI)</measure>
    <time_frame>Week 24</time_frame>
    <description>The LEI was developed specifically for use in PsA. It measures enthesitis at 6 sites (lateral epicondyle, left and right; medial femoral condyle, left and right; Achilles tendon insertion, left and right). Each site was assigned a score of 0 (absent) or 1 (present); the results from each site were then added to produce a total score (range 0 to 6). So, &quot;0&quot; indicates good score here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Itch Numeric Rating Scale (NRS)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable.&quot; Overall severity of a participants itching from psoriasis was indicated by circling the number that best described the worst level of itching in the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tender Joint Count (TJC)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Swollen Joint Count (SJC)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participants Assessment of Pain Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The pain VAS is a participant-administered single-item scale designed to measure current joint pain from Psoriatic arthritis (PsA) using a 100-millimeter(mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by marking a vertical tick on the horizontal 100-mm scale, where the left end from 0 mm (no pain) to right end 100 mm (worst possible joint pain). LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patients Global Assessment of Disease Activity VAS</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The patient's overall assessment of his or her PsA activity will be recorded using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physicians Global Assessment of Disease Activity VAS</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The investigator will be asked to give an overall assessment of the severity of the participant's current PsA activity using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-Reactive Protein (CRP)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>C-reactive protein (CRP) is a disease related biomarker and measured in milligrams per liter. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score-CRP (DAS28-CRP)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The DAS28-CRP is a measure of disease activity in 28 joints that consists of a composite numerical score with the following variables: TJC28, SJC28, hs-CRP (measured in mg/L), and Participant's Global Assessment of Disease Activity recorded by participants on a 0 to 100 millimeter (mm) VAS. For DAS28-CRP, the Tender Joint Count 28 (TJC28) and Swollen Joint Count (SJC28) are a subset of TJC and SJC, and include 14 joints on each side of the body: 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. DAS28 values range from 0 to 9.4. Higher values indicate more severe symptoms and greater functional impairment. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The BASDAI is a self-administered measure used to answer 6 questions with a 0 to 10 centimeter (cm) VAS pertaining to the 5 major symptoms of axial activity. To give each symptom equal weighting, the mean of the 2 scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI Score. BASDAI ranges from 0-10. Higher scores represent greater disease activity. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fatigue Severity Numeric Rating Scale (NRS) Score</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The Fatigue Severity NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no fatigue&quot; and 10 representing &quot;as bad as you can imagine.&quot; Participants rated their fatigue (feeling tired or worn out) by circling the 1 number that described their worst level of fatigue during the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Physical Component Summary (PCS)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Mental Component Summary (MCS)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)</measure>
    <time_frame>Week 24</time_frame>
    <description>Number of participants with positive treatment emergent anti-ixekizumab antibodies was summarized by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK):Minimum Observed Serum Concentration at Steady State (Ctrough,ss) of Ixekizumab</measure>
    <time_frame>All immunogenicity samples post the first Ixekizumab dose (Week 4, 12, 24, 36, and 52) and PK samples collected per dedicated sparse sampling plan (4-5 samples per patient) across Weeks 1 through 24 and Early termination visit (ETV)</time_frame>
    <description>The Ctrough is the minimum observed serum concentration at steady state of Ixekizumab. The Ctrough at Week 24 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration-Time Curve for Dosing Interval (Tau) at Steady State [AUC(Tau,Steady State)] of Ixekizumab</measure>
    <time_frame>All immunogenicity samples post the first Ixekizumab dose (Week 4, 12, 24, 36, and 52) and PK samples collected per dedicated sparse sampling plan (4-5 samples per patient) across Weeks 1 through 24 and Early termination visit (ETV)</time_frame>
    <description>The AUC(Tau,Steady State) is the area under the concentration-time curve for dosing interval (Tau) at steady state of ixekizumab (Tau is 28 days for 80 mg Q4W cohort, and is 14 days for 80mg Q2W cohort, respectively).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR 20</measure>
    <time_frame>Week 52 and Week 156</time_frame>
    <description>ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR 50</measure>
    <time_frame>Week 52 and Week 156</time_frame>
    <description>ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR 70</measure>
    <time_frame>Week 52 and Week 156</time_frame>
    <description>ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">363</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Ixekizumab 80 milligram (mg) every 2 Weeks (Q2W)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinded Treatment Period (Week(wk) 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22, and 24.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q2W and IR from ixekizumab 80 mg Q2W who continued on ixekizumab 80 mg Q2W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q2W given on Wks 16,18,20,22,24. Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q2W at week 0 and continued on ixe 80 mg Q2W during the Extension Period. Pts who received ixekizumab 80 mg Q2W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ixekizumab 80 mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinded Treatment Period (Week 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q4W given on Wks 4, 8 and 12 alternating with placebo for ixe injections Q4W given on Wks 2,6,10,14,18, and 22.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q4W and IR from ixekizumab 80 mg Q4W who continued on ixekizumab 80 mg Q4W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q4W given on Wks 16 and 20 alternating with placebo for ixe injections Q4W given on Wks 18 and 22.Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q4W at week 0 and continued on ixe 80 mg Q4W during the Extension Period.Pts who received ixekizumab 80 mg Q4W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blinded Treatment Period (Wk 0-24): Pts received placebo for Ixe as 2 SC injections followed by 1 SC injection Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22 and 24. Pts initially randomized to placebo treatment group in the double blind treatment period,flagged as IR at Wk 16,re-randomized to ixe 80 mg Q2W/Q4W for the remainder of the current period and following period. Extended Treatment Period (Wk 24-156): Pts who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W/Q4W during the Extension Period.Pts who remained on placebo at the completion of the double blind treatment period received the first dose of ixe (160 mg starting dose) at Wk 24.Pts who were IRs at Wk 16 and were re-randomized to ixe at Wk 16 received the first dose of ixe (160 mg starting dose) at Wk 16. Pts who received placebo,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Ixekizumab 80 mg Q4W</arm_group_label>
    <arm_group_label>Ixekizumab 80 milligram (mg) every 2 Weeks (Q2W)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixekizumab 80 mg Q4W</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Ixekizumab 80 mg Q4W</arm_group_label>
    <other_name>LY2439821</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixekizumab 80 mg Q2W</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Ixekizumab 80 milligram (mg) every 2 Weeks (Q2W)</arm_group_label>
    <other_name>LY2439821</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presents with established diagnosis of active psoriatic arthritis (PsA) for at least 6
             months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria

          -  Active PsA defined as the presence of at least 3 tender and at least 3 swollen joints

          -  Presence of active psoriatic skin lesion or a history of plaque psoriasis (Ps)

          -  Men must agree to use a reliable method of birth control or remain abstinent during
             the study

          -  Women must agree to use reliable birth control or remain abstinent during the study
             and for at least 12 weeks after stopping treatment

          -  Have been treated with 1 or more conventional disease-modifying antirheumatic drugs
             (cDMARDs)

          -  Have had prior treatment with at least 1 and not more than 2 tumor necrosis factor
             (TNF) inhibitors. The participant must have discontinued at least 1 TNF inhibitor due
             to either an inadequate response (based on a minimum of 12 weeks on therapy) or
             documented intolerance.

        Exclusion Criteria:

          -  Current use of biologic agents for treatment of Ps or PsA

          -  Inadequate response to greater than 2 biologic DMARDs

          -  Current use of more than one cDMARDs

          -  Diagnosis of active inflammatory arthritic syndromes or spondyloarthropathies other
             than PsA

          -  Have received treatment with interleukin (IL) -17 or IL12/23 targeted monoclonal
             antibody (MAb) therapy

          -  Serious disorder or illness other than psoriatic arthritis

          -  Serious infection within the last 3 months

          -  Breastfeeding or nursing (lactating) women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Associates PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research, PLLC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Rock Diagnostic Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Purushotham &amp; Akther Kotha MD Inc</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Rheumatology Medical Group</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office: Dr Robin K Dore</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of South Florida</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeffrey Alper MD Research</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Treatment Center, PA</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Medical Clinic PA</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542-7505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Rheumatology and Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians Clinic of Iowa</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Community Research. Inc</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Arthritis Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klein and Associates MD, PA</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klein and Associates MD, PA</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beals Institute PC</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North MS Medical Clinics, Inc.</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glacier View Research Institute</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Research Collaboration, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Physicians</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Coastal Research</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis, Rheumatic &amp; Back Disease Associates</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Rehabilitation &amp; Rheumatology, PC</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma Immunology of Rochester, AAIR Research Ctr</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of Long Island</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <zip>11787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis Consultants of the Carolinas</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research, PLLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Hickory, LLC</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STAT Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMA Medical Specialists, LLC</name>
      <address>
        <city>Limerick</city>
        <state>Pennsylvania</state>
        <zip>19468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Reading, LLC</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Regional Center for Arthritis &amp; Osteoarthritis</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104-3499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramesh C. Gupta MD</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Rheumatology Research PA</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Regional Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Care &amp; Diagnostic Center P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Institute for Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Associates LLP</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kadlec Clinic Rheumatology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest PLLC</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology and Immunotherapy Center</name>
      <address>
        <city>Franklin</city>
        <state>Wisconsin</state>
        <zip>53132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coast Joint Care</name>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research</name>
      <address>
        <city>Camberwell</city>
        <state>Victoria</state>
        <zip>3124</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Czech Prague, s.r.o.</name>
      <address>
        <city>Praha</city>
        <zip>13000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICAL PLUS, s.r.o.</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PV-MEDICAL s.r.o. Revmatologicka ambulance</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau, CHRU de Tours</name>
      <address>
        <city>Chambray-lès-Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier-Hopital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru De Nantes Hotel-Dieu</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris CEDEX 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universität Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet</name>
      <address>
        <city>Herne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44649</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden-Friedrichstadt Städtisches Klinikum</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig - Universitätsklinikum</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HRF Hamburger Rheuma Forschungszentrum</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Gaetano Pini</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Medyczne S.C.</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medica pro Familia Sp z o.o. S.K.A</name>
      <address>
        <city>Krakow</city>
        <zip>30002</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AI Centrum Medyczne</name>
      <address>
        <city>Poznan</city>
        <zip>61-113</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medica pro Familia Sp z o.o. S.K.A</name>
      <address>
        <city>Warszawa</city>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheuma Medicus Zakład Opieki Zdrowotnej</name>
      <address>
        <city>Warszawa</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Luisa</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Mental Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques De Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario A Coruña, CHUAC</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Malaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi-Mei Hospital, Liouying</name>
      <address>
        <city>Tainan City</city>
        <state>Yongkang Dist</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Kaohsiung</name>
      <address>
        <city>Kaohsiung City (r.o.c)</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linkou</name>
      <address>
        <city>Taoyuan City</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basildon and Thurrock University Hospital</name>
      <address>
        <city>Basildon</city>
        <state>Essex</state>
        <zip>SS16 5NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George Hospital</name>
      <address>
        <city>Goodmayes</city>
        <state>Essex</state>
        <zip>IG7 4DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Harlow</city>
        <state>Essex</state>
        <zip>CM20 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whipps Cross University Hospital</name>
      <address>
        <city>London</city>
        <state>Surrey</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <state>West Midlands</state>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Allerton Hospital</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.lillytrialguide.com/EN-us/studies/arthritis/rhbe</url>
    <description>Click here for more information about this study: A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis</description>
  </link>
  <verification_date>September 1, 2019</verification_date>
  <study_first_submitted>October 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <results_first_submitted>September 6, 2017</results_first_submitted>
  <results_first_submitted_qc>November 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 14, 2017</results_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ixekizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and european union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ixekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment Period</title>
          <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 subcutaneous (SC) injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab every 2 Weeks (Q2W) given on Weeks 2, 4, 6, 8, 10, 12,14, 16, 18, 20, 22, and 24.</description>
        </group>
        <group group_id="P2">
          <title>Ixekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment Period</title>
          <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14, 18, and 22.</description>
        </group>
        <group group_id="P3">
          <title>Placebo (PBO) - Blinded Treatment Period</title>
          <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24.</description>
        </group>
        <group group_id="P4">
          <title>Ixe 80 mg Q2W - Blinded Treatment Period IR</title>
          <description>Week 16 inadequate responders from the placebo treatment group who were re-randomized (1:1) to ixekizumab 80 mg Q2W and IR from ixekizumab 80 mg Q2W who continued on ixekizumab 80 mg Q2W. Participants received rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20, 22, and 24.</description>
        </group>
        <group group_id="P5">
          <title>Ixe 80 mg Q4W - Blinded Treatment Period IR</title>
          <description>Week 16 inadequate responders from the placebo treatment group who were re-randomized (1:1) to ixekizumab 80 mg Q4W and IR from ixekizumab 80 mg Q4W who continued on ixekizumab 80 mg Q4W. Participants received rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22.</description>
        </group>
        <group group_id="P6">
          <title>PBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IR</title>
          <description>Participants initially randomized to placebo treatment group in the double blind treatment period who were flagged as inadequate responders at week 16 were re-randomized to ixekizumab 80 mg Q2W for the remainder of the current period and following period.</description>
        </group>
        <group group_id="P7">
          <title>PBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IR</title>
          <description>Participants initially randomized to placebo treatment group in the double blind treatment period who were flagged as inadequate responders at week 16 were re-randomized to ixekizumab 80 mg Q4W for the remainder of the current period and following period.</description>
        </group>
        <group group_id="P8">
          <title>Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period</title>
          <description>Participants who were randomized to ixekizumab 80 mg Q2W at week 0 and continued on ixekizumab 80 mg Q2W during the Extension Period.</description>
        </group>
        <group group_id="P9">
          <title>Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period</title>
          <description>Participants who were randomized to ixekizumab 80 mg Q4W at week 0 and continued on ixekizumab 80 mg Q4W during the Extension Period.</description>
        </group>
        <group group_id="P10">
          <title>Placebo/ Ixe 80 mg Q2W - Extended Treatment Period</title>
          <description>Participants who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W during the Extension Period.
Participants who remained on placebo at the completion of the double blind treatment period received the first dose of ixekizumab (160 mg starting dose) at Week 24.
Participants who were IRs at Week 16 and were re-randomized to ixekizumab at Week 16 received the first dose of ixekizumab (160 mg starting dose) at Week 16.</description>
        </group>
        <group group_id="P11">
          <title>Placebo/ Ixe 80 mg Q4W - Extended Treatment Period</title>
          <description>Participants who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q4W during the Extension Period.
Participants who remained on placebo at the completion of the double blind treatment period received the first dose of ixekizumab (160 mg starting dose) at Week 24.
Participants who were IRs at Week 16 and were re-randomized to ixekizumab at Week 16 received the first dose of ixekizumab (160 mg starting dose) at Week 16.</description>
        </group>
        <group group_id="P12">
          <title>Ixe 80 mg Q2W - Post Treatment Follow-Up Period</title>
          <description>Participants who received ixekizumab 80 mg Q2W prior to entering the post-treatment follow-up period, who were either completed the study or discontinued the study early entered the post-treatment follow-up period (a 12-24 week period after their last scheduled treatment visit).</description>
        </group>
        <group group_id="P13">
          <title>Ixe 80 mg Q4W - Post Treatment Follow-Up Period</title>
          <description>Participants who received ixekizumab 80 mg Q4W prior to entering the post-treatment follow-up period, who were either completed the study or discontinued the study early entered the post-treatment follow-up period (a 12-24 week period after their last scheduled treatment visit).</description>
        </group>
        <group group_id="P14">
          <title>PBO - Post Treatment Follow-Up Period</title>
          <description>Participants who received PBO prior to entering the post-treatment follow-up period, who were either completed the study or discontinued the study early entered the post-treatment follow-up period (a 12-24 week period after their last scheduled treatment visit).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double Blind Treatment (Week 0-24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="118"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Atleast One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="118"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="94"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure To Meet Randomization</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>IR (Week 16-24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Only IR participants were included.</participants>
                <participants group_id="P2" count="0">Only IR participants were included.</participants>
                <participants group_id="P3" count="0">Only IR participants were included.</participants>
                <participants group_id="P4" count="17">IR from ixekizumab 80 mg Q2W only.</participants>
                <participants group_id="P5" count="15">IR from ixekizumab 80 mg Q4W only.</participants>
                <participants group_id="P6" count="16">IR from placebo who re-randomized (1:1) to ixekizumab 80 mg Q2W.</participants>
                <participants group_id="P7" count="16">IR from placebo who re-randomized (1:1) to ixekizumab 80 mg Q4W.</participants>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-Term Extension Period (Week 24-156)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0">Only included combined extension participants.</participants>
                <participants group_id="P5" count="0">Only included combined extension participants.</participants>
                <participants group_id="P6" count="0">Only included combined extension participants.</participants>
                <participants group_id="P7" count="0">Only included combined extension participants.</participants>
                <participants group_id="P8" count="107">IxeQ2W participants who entered the long-term extension period.</participants>
                <participants group_id="P9" count="111">IxeQ4W participants who entered the long-term extension period.</participants>
                <participants group_id="P10" count="46">Placebo/IxeQ2W participants who entered the long-term extension period.</participants>
                <participants group_id="P11" count="46">Placebo/IxeQ4W participants who entered the long-term extension period.</participants>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="55"/>
                <participants group_id="P9" count="70"/>
                <participants group_id="P10" count="20"/>
                <participants group_id="P11" count="23"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="52"/>
                <participants group_id="P9" count="41"/>
                <participants group_id="P10" count="26"/>
                <participants group_id="P11" count="23"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="32"/>
                <participants group_id="P9" count="25"/>
                <participants group_id="P10" count="19"/>
                <participants group_id="P11" count="18"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="9"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown/Missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-Up Period (Up to 12-24 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0">Only included post-treatment follow-up participants.</participants>
                <participants group_id="P9" count="0">Only included post-treatment follow-up participants.</participants>
                <participants group_id="P10" count="0">Only included post-treatment follow-up participants.</participants>
                <participants group_id="P11" count="0">Only included post-treatment follow-up participants.</participants>
                <participants group_id="P12" count="142">IxeQ2W participants who entered post-treatment follow-up.</participants>
                <participants group_id="P13" count="145">IxeQ4W participants who entered post-treatment follow-up.</participants>
                <participants group_id="P14" count="17">PBO participants who entered post-treatment follow-up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="133"/>
                <participants group_id="P13" count="137"/>
                <participants group_id="P14" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="9"/>
                <participants group_id="P13" count="8"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown/Missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="4"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
        </group>
        <group group_id="B2">
          <title>Ixekizumab 80 mg Q4W</title>
          <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
        </group>
        <group group_id="B3">
          <title>Ixekizumab 80 mg Q2W</title>
          <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="118"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="123"/>
            <count group_id="B4" value="363"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" spread="10.39"/>
                    <measurement group_id="B2" value="52.6" spread="13.57"/>
                    <measurement group_id="B3" value="51.7" spread="11.85"/>
                    <measurement group_id="B4" value="51.9" spread="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="324"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="332"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20)</title>
        <description>ACR20 response is defined as a greater than or equal to (≥) 20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain visual analog scale (VAS), Participant's Global Assessment of Disease Activity VAS (PatGA), Physician's Global Assessment of the Disease Activity VAS (PGA), Participant's Assessment of Physical Function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or Acute Phase Reactant as measured by high sensitivity C-reactive protein (hs-CRP).</description>
        <time_frame>Week 24</time_frame>
        <population>All randomized participants. Non-responder Imputation (NRI) is applied for inadequate responders at Week 16 and participants who had missing data at Week 24 for any reason including discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20)</title>
          <description>ACR20 response is defined as a greater than or equal to (≥) 20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain visual analog scale (VAS), Participant's Global Assessment of Disease Activity VAS (PatGA), Physician's Global Assessment of the Disease Activity VAS (PGA), Participant's Assessment of Physical Function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or Acute Phase Reactant as measured by high sensitivity C-reactive protein (hs-CRP).</description>
          <population>All randomized participants. Non-responder Imputation (NRI) is applied for inadequate responders at Week 16 and participants who had missing data at Week 24 for any reason including discontinuation.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5"/>
                    <measurement group_id="O2" value="53.3"/>
                    <measurement group_id="O3" value="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>model includes: treatment, geographic region, and tumor necrosis factor inhibitor (TNFi) experience (inadequate responder to 1 TNFi, inadequate responder to 2 TNFi, or intolerance to a TNFi).</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>1) uses a Wald's test , 2) Non-responder imputation (NRI) was used to calculate the response rates.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.65</ci_lower_limit>
            <ci_upper_limit>8.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>model includes: treatment, geographic region, and TNFi experience (inadequate responder to 1 TNFi, inadequate responder to 2 TNFi, or intolerance to a TNFi)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>1) uses a Wald's test , 2) Non-responder imputation (NRI) was used to calculate the response rates.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.12</ci_lower_limit>
            <ci_upper_limit>6.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score</title>
        <description>HAQ-DI is a participant reported questionnaire that measures disease-associated disability(physical function).It consists of 24 questions with 8 domains: dressing/grooming,arising,eating,walking,hygiene,reach,grip and other daily activities. The disability section scores the participant's self-perception on degree of difficulty (0=without any difficulty,1=with some difficulty,2=with much difficulty,3=unable to do)covering the 8 domains.The HAQ-DI is a composite ranging from 0-3 with lower scores indicating less functional disability.The reported use of special aids/devices and/or the need for assistance of another person to perform these activities is assessed.Least Square (LS) mean calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment,baseline score,geographic region, TNFi experience,visit, treatment-by-visit interaction(itcn), geographic region-by-visit itcn,TNFi experience-by-visit itcn and baseline score-by-visit itcn.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score</title>
          <description>HAQ-DI is a participant reported questionnaire that measures disease-associated disability(physical function).It consists of 24 questions with 8 domains: dressing/grooming,arising,eating,walking,hygiene,reach,grip and other daily activities. The disability section scores the participant's self-perception on degree of difficulty (0=without any difficulty,1=with some difficulty,2=with much difficulty,3=unable to do)covering the 8 domains.The HAQ-DI is a composite ranging from 0-3 with lower scores indicating less functional disability.The reported use of special aids/devices and/or the need for assistance of another person to perform these activities is assessed.Least Square (LS) mean calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment,baseline score,geographic region, TNFi experience,visit, treatment-by-visit interaction(itcn), geographic region-by-visit itcn,TNFi experience-by-visit itcn and baseline score-by-visit itcn.</description>
          <population>All randomized participants.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.08"/>
                    <measurement group_id="O2" value="-0.6" spread="0.07"/>
                    <measurement group_id="O3" value="-0.4" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ACR20</title>
        <description>ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants. NRI is applied for inadequate responders at Week 16 and participants who had missing data at Week 24 for any reason including discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ACR20</title>
          <description>ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
          <population>All randomized participants. NRI is applied for inadequate responders at Week 16 and participants who had missing data at Week 24 for any reason including discontinuation.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 50 Index (ACR50)</title>
        <description>ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
        <time_frame>Week 24</time_frame>
        <population>All randomized participants. NRI is applied for inadequate responders at Week 16 and participants who had missing data at Week 24 for any reason including discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 50 Index (ACR50)</title>
          <description>ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
          <population>All randomized participants. NRI is applied for inadequate responders at Week 16 and participants who had missing data at Week 24 for any reason including discontinuation.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="35.2"/>
                    <measurement group_id="O3" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 70 Index (ACR70)</title>
        <description>ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
        <time_frame>Week 24</time_frame>
        <population>All randomized participants. NRI is applied for inadequate responders at Week 16 and participants who had missing data at Week 24 for any reason including discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 70 Index (ACR70)</title>
          <description>ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
          <population>All randomized participants. NRI is applied for inadequate responders at Week 16 and participants who had missing data at Week 24 for any reason including discontinuation.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="22.1"/>
                    <measurement group_id="O3" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75</title>
        <description>The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI compared to their baseline measures.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants with baseline psoriatic lesion(s) involving ≥3% body surface area (BSA). NRI is applied for inadequate responders at Week 16 and participants who had missing data at Week 24 for any reason including discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75</title>
          <description>The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI compared to their baseline measures.</description>
          <population>All randomized participants with baseline psoriatic lesion(s) involving ≥3% body surface area (BSA). NRI is applied for inadequate responders at Week 16 and participants who had missing data at Week 24 for any reason including discontinuation.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="57.4"/>
                    <measurement group_id="O3" value="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Minimal Disease Activity (MDA)</title>
        <description>It uses a composite of 7 key outcome measures (includes PASI) used in PsA to encompass all of the domains of the disease to measure the overall state of a patients' disease. The LEI is used to assess tender entheseal points. Patients are classified as achieving MDA if they fulfill 5 of 7 outcome measures: 1. TJC ≤1, 2. SJC ≤1, 3. PASI total score ≤1 or BSA ≤3, 4. patient pain VAS score of ≤15, 5. patient global VAS score of ≤20, 6. HAQ-DI score ≤0.5, 7. tender entheseal points (6 entheseal points) ≤1.</description>
        <time_frame>Week 24</time_frame>
        <population>All randomized participants. NRI is applied for inadequate responders at Week 16 and participants who had missing data at Week 24 for any reason including discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Minimal Disease Activity (MDA)</title>
          <description>It uses a composite of 7 key outcome measures (includes PASI) used in PsA to encompass all of the domains of the disease to measure the overall state of a patients' disease. The LEI is used to assess tender entheseal points. Patients are classified as achieving MDA if they fulfill 5 of 7 outcome measures: 1. TJC ≤1, 2. SJC ≤1, 3. PASI total score ≤1 or BSA ≤3, 4. patient pain VAS score of ≤15, 5. patient global VAS score of ≤20, 6. HAQ-DI score ≤0.5, 7. tender entheseal points (6 entheseal points) ≤1.</description>
          <population>All randomized participants. NRI is applied for inadequate responders at Week 16 and participants who had missing data at Week 24 for any reason including discontinuation.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Complete Resolution in Enthesitis as Assessed by the Leeds Enthesitis Index (LEI)</title>
        <description>The LEI was developed specifically for use in PsA. It measures enthesitis at 6 sites (lateral epicondyle, left and right; medial femoral condyle, left and right; Achilles tendon insertion, left and right). Each site was assigned a score of 0 (absent) or 1 (present); the results from each site were then added to produce a total score (range 0 to 6). So, &quot;0&quot; indicates good score here.</description>
        <time_frame>Week 24</time_frame>
        <population>All randomized participants who had baseline enthesitis, baseline LEI score and post baseline LEI score data. NRI is applied for inadequate responders at Week 16 and participants who had missing data at Week 24 for any reason including discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Complete Resolution in Enthesitis as Assessed by the Leeds Enthesitis Index (LEI)</title>
          <description>The LEI was developed specifically for use in PsA. It measures enthesitis at 6 sites (lateral epicondyle, left and right; medial femoral condyle, left and right; Achilles tendon insertion, left and right). Each site was assigned a score of 0 (absent) or 1 (present); the results from each site were then added to produce a total score (range 0 to 6). So, &quot;0&quot; indicates good score here.</description>
          <population>All randomized participants who had baseline enthesitis, baseline LEI score and post baseline LEI score data. NRI is applied for inadequate responders at Week 16 and participants who had missing data at Week 24 for any reason including discontinuation.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7"/>
                    <measurement group_id="O2" value="35.3"/>
                    <measurement group_id="O3" value="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Itch Numeric Rating Scale (NRS)</title>
        <description>The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable.&quot; Overall severity of a participants itching from psoriasis was indicated by circling the number that best described the worst level of itching in the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who had baseline psoriatic lesion(s) involving &gt;=3% BSA, baseline itch NRS score and post baseline itch NRS score data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Itch Numeric Rating Scale (NRS)</title>
          <description>The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable.&quot; Overall severity of a participants itching from psoriasis was indicated by circling the number that best described the worst level of itching in the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
          <population>All randomized participants who had baseline psoriatic lesion(s) involving &gt;=3% BSA, baseline itch NRS score and post baseline itch NRS score data.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.40"/>
                    <measurement group_id="O2" value="-3.4" spread="0.39"/>
                    <measurement group_id="O3" value="-3.3" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tender Joint Count (TJC)</title>
        <description>TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and post baseline TJC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tender Joint Count (TJC)</title>
          <description>TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
          <population>All randomized participants with baseline and post baseline TJC data.</population>
          <units>Tender Joint Count</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="1.96"/>
                    <measurement group_id="O2" value="-12.7" spread="1.87"/>
                    <measurement group_id="O3" value="-12.5" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Swollen Joint Count (SJC)</title>
        <description>SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and post baseline SJC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Swollen Joint Count (SJC)</title>
          <description>SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
          <population>All randomized participants with baseline and post baseline SJC data.</population>
          <units>Swollen Joint Count</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="1.05"/>
                    <measurement group_id="O2" value="-8.5" spread="0.99"/>
                    <measurement group_id="O3" value="-7.4" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participants Assessment of Pain Visual Analog Scale (VAS)</title>
        <description>The pain VAS is a participant-administered single-item scale designed to measure current joint pain from Psoriatic arthritis (PsA) using a 100-millimeter(mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by marking a vertical tick on the horizontal 100-mm scale, where the left end from 0 mm (no pain) to right end 100 mm (worst possible joint pain). LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and post baseline TJC and SJC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participants Assessment of Pain Visual Analog Scale (VAS)</title>
          <description>The pain VAS is a participant-administered single-item scale designed to measure current joint pain from Psoriatic arthritis (PsA) using a 100-millimeter(mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by marking a vertical tick on the horizontal 100-mm scale, where the left end from 0 mm (no pain) to right end 100 mm (worst possible joint pain). LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
          <population>All randomized participants with baseline and post baseline TJC and SJC data.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.4" spread="3.97"/>
                    <measurement group_id="O2" value="-36.9" spread="3.74"/>
                    <measurement group_id="O3" value="-33.5" spread="3.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patients Global Assessment of Disease Activity VAS</title>
        <description>The patient's overall assessment of his or her PsA activity will be recorded using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and post baseline Patients Global Assessment of Disease Activity VAS score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patients Global Assessment of Disease Activity VAS</title>
          <description>The patient's overall assessment of his or her PsA activity will be recorded using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
          <population>All randomized participants with baseline and post baseline Patients Global Assessment of Disease Activity VAS score.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.0" spread="3.91"/>
                    <measurement group_id="O2" value="-40.7" spread="3.68"/>
                    <measurement group_id="O3" value="-37.3" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physicians Global Assessment of Disease Activity VAS</title>
        <description>The investigator will be asked to give an overall assessment of the severity of the participant's current PsA activity using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and post baseline Physicians Global Assessment of Disease Activity VAS score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physicians Global Assessment of Disease Activity VAS</title>
          <description>The investigator will be asked to give an overall assessment of the severity of the participant's current PsA activity using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
          <population>All randomized participants with baseline and post baseline Physicians Global Assessment of Disease Activity VAS score.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.3" spread="3.98"/>
                    <measurement group_id="O2" value="-40.0" spread="3.85"/>
                    <measurement group_id="O3" value="-37.9" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-Reactive Protein (CRP)</title>
        <description>C-reactive protein (CRP) is a disease related biomarker and measured in milligrams per liter. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and post baseline CRP data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-Reactive Protein (CRP)</title>
          <description>C-reactive protein (CRP) is a disease related biomarker and measured in milligrams per liter. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
          <population>All randomized participants with baseline and post baseline CRP data.</population>
          <units>milligram per liter (mg/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="1.87"/>
                    <measurement group_id="O2" value="-11.8" spread="1.76"/>
                    <measurement group_id="O3" value="-9.8" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score-CRP (DAS28-CRP)</title>
        <description>The DAS28-CRP is a measure of disease activity in 28 joints that consists of a composite numerical score with the following variables: TJC28, SJC28, hs-CRP (measured in mg/L), and Participant's Global Assessment of Disease Activity recorded by participants on a 0 to 100 millimeter (mm) VAS. For DAS28-CRP, the Tender Joint Count 28 (TJC28) and Swollen Joint Count (SJC28) are a subset of TJC and SJC, and include 14 joints on each side of the body: 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. DAS28 values range from 0 to 9.4. Higher values indicate more severe symptoms and greater functional impairment. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants who had baseline and post baseline DAS28-CRP data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score-CRP (DAS28-CRP)</title>
          <description>The DAS28-CRP is a measure of disease activity in 28 joints that consists of a composite numerical score with the following variables: TJC28, SJC28, hs-CRP (measured in mg/L), and Participant's Global Assessment of Disease Activity recorded by participants on a 0 to 100 millimeter (mm) VAS. For DAS28-CRP, the Tender Joint Count 28 (TJC28) and Swollen Joint Count (SJC28) are a subset of TJC and SJC, and include 14 joints on each side of the body: 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. DAS28 values range from 0 to 9.4. Higher values indicate more severe symptoms and greater functional impairment. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
          <population>All randomized participants who had baseline and post baseline DAS28-CRP data.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.20"/>
                    <measurement group_id="O2" value="-2.1" spread="0.19"/>
                    <measurement group_id="O3" value="-1.8" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score</title>
        <description>The BASDAI is a self-administered measure used to answer 6 questions with a 0 to 10 centimeter (cm) VAS pertaining to the 5 major symptoms of axial activity. To give each symptom equal weighting, the mean of the 2 scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI Score. BASDAI ranges from 0-10. Higher scores represent greater disease activity. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants who had baseline axial involvement defined as baseline BASDAI score &gt;4, baseline BASDAI score and post baseline BASDAI score data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score</title>
          <description>The BASDAI is a self-administered measure used to answer 6 questions with a 0 to 10 centimeter (cm) VAS pertaining to the 5 major symptoms of axial activity. To give each symptom equal weighting, the mean of the 2 scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI Score. BASDAI ranges from 0-10. Higher scores represent greater disease activity. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
          <population>All randomized participants who had baseline axial involvement defined as baseline BASDAI score &gt;4, baseline BASDAI score and post baseline BASDAI score data.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="0.38"/>
                    <measurement group_id="O2" value="-3.7" spread="0.36"/>
                    <measurement group_id="O3" value="-3.6" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fatigue Severity Numeric Rating Scale (NRS) Score</title>
        <description>The Fatigue Severity NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no fatigue&quot; and 10 representing &quot;as bad as you can imagine.&quot; Participants rated their fatigue (feeling tired or worn out) by circling the 1 number that described their worst level of fatigue during the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants who had baseline and post baseline fatigue NRS data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fatigue Severity Numeric Rating Scale (NRS) Score</title>
          <description>The Fatigue Severity NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no fatigue&quot; and 10 representing &quot;as bad as you can imagine.&quot; Participants rated their fatigue (feeling tired or worn out) by circling the 1 number that described their worst level of fatigue during the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
          <population>All randomized participants who had baseline and post baseline fatigue NRS data.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.37"/>
                    <measurement group_id="O2" value="-2.0" spread="0.35"/>
                    <measurement group_id="O3" value="-2.1" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Physical Component Summary (PCS)</title>
        <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants who had baseline and post baseline PCS data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Physical Component Summary (PCS)</title>
          <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
          <population>All randomized participants who had baseline and post baseline PCS data.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.36"/>
                    <measurement group_id="O2" value="8.9" spread="1.29"/>
                    <measurement group_id="O3" value="8.2" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Mental Component Summary (MCS)</title>
        <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants who had baseline and post baseline MCS data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Mental Component Summary (MCS)</title>
          <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.</description>
          <population>All randomized participants who had baseline and post baseline MCS data.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.32"/>
                    <measurement group_id="O2" value="3.6" spread="1.24"/>
                    <measurement group_id="O3" value="4.0" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)</title>
        <description>Number of participants with positive treatment emergent anti-ixekizumab antibodies was summarized by treatment group.</description>
        <time_frame>Week 24</time_frame>
        <population>All randomized participants who received at least 1 dose of ixekizumab and had evaluable anti-ixekizumab antibody measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy and re-randomized (1:1) to either ixekizumab group, receiving a starting dose of 160 mg at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or Q4W (with placebo every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)</title>
          <description>Number of participants with positive treatment emergent anti-ixekizumab antibodies was summarized by treatment group.</description>
          <population>All randomized participants who received at least 1 dose of ixekizumab and had evaluable anti-ixekizumab antibody measurement.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK):Minimum Observed Serum Concentration at Steady State (Ctrough,ss) of Ixekizumab</title>
        <description>The Ctrough is the minimum observed serum concentration at steady state of Ixekizumab. The Ctrough at Week 24 was reported.</description>
        <time_frame>All immunogenicity samples post the first Ixekizumab dose (Week 4, 12, 24, 36, and 52) and PK samples collected per dedicated sparse sampling plan (4-5 samples per patient) across Weeks 1 through 24 and Early termination visit (ETV)</time_frame>
        <population>The PK Population included all enrolled participants who received at least one dose of the study drug and had evaluable ixekizumab PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK):Minimum Observed Serum Concentration at Steady State (Ctrough,ss) of Ixekizumab</title>
          <description>The Ctrough is the minimum observed serum concentration at steady state of Ixekizumab. The Ctrough at Week 24 was reported.</description>
          <population>The PK Population included all enrolled participants who received at least one dose of the study drug and had evaluable ixekizumab PK data.</population>
          <units>micograms per milliliter (mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="79.1"/>
                    <measurement group_id="O2" value="7.96" spread="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration-Time Curve for Dosing Interval (Tau) at Steady State [AUC(Tau,Steady State)] of Ixekizumab</title>
        <description>The AUC(Tau,Steady State) is the area under the concentration-time curve for dosing interval (Tau) at steady state of ixekizumab (Tau is 28 days for 80 mg Q4W cohort, and is 14 days for 80mg Q2W cohort, respectively).</description>
        <time_frame>All immunogenicity samples post the first Ixekizumab dose (Week 4, 12, 24, 36, and 52) and PK samples collected per dedicated sparse sampling plan (4-5 samples per patient) across Weeks 1 through 24 and Early termination visit (ETV)</time_frame>
        <population>The PK Population included all enrolled participants who received at least one dose of the study drug and had evaluable ixekizumab PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixekizumab 80 mg Q4W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22</description>
          </group>
          <group group_id="O2">
            <title>Ixekizumab 80 mg Q2W</title>
            <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration-Time Curve for Dosing Interval (Tau) at Steady State [AUC(Tau,Steady State)] of Ixekizumab</title>
          <description>The AUC(Tau,Steady State) is the area under the concentration-time curve for dosing interval (Tau) at steady state of ixekizumab (Tau is 28 days for 80 mg Q4W cohort, and is 14 days for 80mg Q2W cohort, respectively).</description>
          <population>The PK Population included all enrolled participants who received at least one dose of the study drug and had evaluable ixekizumab PK data.</population>
          <units>mcg*day/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141" spread="59.3"/>
                    <measurement group_id="O2" value="143" spread="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ACR 20</title>
        <description>ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
        <time_frame>Week 52 and Week 156</time_frame>
        <population>All randomized participants. Non-responder Imputation (NRI) is applied for inadequate responders at week 16 and participants who discontinued on or prior to week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period</title>
            <description>Participants who were randomized to ixekizumab 80 mg Q2W at week 0 and continued on ixekizumab 80 mg Q2W during the Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period</title>
            <description>Participants who were randomized to ixekizumab 80 mg Q4W at week 0 and continued on ixekizumab 80 mg Q4W during the Extension Period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/ Ixe 80 mg Q2W - Extended Treatment Period</title>
            <description>Participants who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W during the Extension Period.
Participants who remained on placebo at the completion of the double blind treatment period received the first dose of ixekizumab (160 mg starting dose) at Week 24.
Participants who were IRs at Week 16 and were re-randomized to ixekizumab at Week 16 received the first dose of ixekizumab (160 mg starting dose) at Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/ Ixe 80 mg Q4W - Extended Treatment Period</title>
            <description>Participants who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q4W during the Extension Period.
Participants who remained on placebo at the completion of the double blind treatment period received the first dose of ixekizumab (160 mg starting dose) at Week 24.
Participants who were IRs at Week 16 and were re-randomized to ixekizumab at Week 16 received the first dose of ixekizumab (160 mg starting dose) at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ACR 20</title>
          <description>ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
          <population>All randomized participants. Non-responder Imputation (NRI) is applied for inadequate responders at week 16 and participants who discontinued on or prior to week 24.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9"/>
                    <measurement group_id="O2" value="67.6"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1"/>
                    <measurement group_id="O2" value="50.5"/>
                    <measurement group_id="O3" value="39.1"/>
                    <measurement group_id="O4" value="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ACR 50</title>
        <description>ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
        <time_frame>Week 52 and Week 156</time_frame>
        <population>All randomized participants. Non-responder Imputation (NRI) is applied for inadequate responders at week 16 and participants who discontinued on or prior to week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period</title>
            <description>Participants who were randomized to ixekizumab 80 mg Q2W at week 0 and continued on ixekizumab 80 mg Q2W during the Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period</title>
            <description>Participants who were randomized to ixekizumab 80 mg Q4W at week 0 and continued on ixekizumab 80 mg Q4W during the Extension Period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/ Ixe 80 mg Q2W - Extended Treatment Period</title>
            <description>Participants who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W during the Extension Period.
Participants who remained on placebo at the completion of the double blind treatment period received the first dose of ixekizumab (160 mg starting dose) at Week 24.
Participants who were IRs at Week 16 and were re-randomized to ixekizumab at Week 16 received the first dose of ixekizumab (160 mg starting dose) at Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/ Ixe 80 mg Q4W - Extended Treatment Period</title>
            <description>Participants who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q4W during the Extension Period.
Participants who remained on placebo at the completion of the double blind treatment period received the first dose of ixekizumab (160 mg starting dose) at Week 24.
Participants who were IRs at Week 16 and were re-randomized to ixekizumab at Week 16 received the first dose of ixekizumab (160 mg starting dose) at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ACR 50</title>
          <description>ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
          <population>All randomized participants. Non-responder Imputation (NRI) is applied for inadequate responders at week 16 and participants who discontinued on or prior to week 24.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3"/>
                    <measurement group_id="O2" value="45.9"/>
                    <measurement group_id="O3" value="34.8"/>
                    <measurement group_id="O4" value="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0"/>
                    <measurement group_id="O2" value="35.1"/>
                    <measurement group_id="O3" value="26.1"/>
                    <measurement group_id="O4" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ACR 70</title>
        <description>ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
        <time_frame>Week 52 and Week 156</time_frame>
        <population>All randomized participants. Non-responder Imputation (NRI) is applied for inadequate responders at week 16 and participants who discontinued on or prior to week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period</title>
            <description>Participants who were randomized to ixekizumab 80 mg Q2W at week 0 and continued on ixekizumab 80 mg Q2W during the Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period</title>
            <description>Participants who were randomized to ixekizumab 80 mg Q4W at week 0 and continued on ixekizumab 80 mg Q4W during the Extension Period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/ Ixe 80 mg Q2W - Extended Treatment Period</title>
            <description>Participants who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W during the Extension Period.
Participants who remained on placebo at the completion of the double blind treatment period received the first dose of ixekizumab (160 mg starting dose) at Week 24.
Participants who were IRs at Week 16 and were re-randomized to ixekizumab at Week 16 received the first dose of ixekizumab (160 mg starting dose) at Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/ Ixe 80 mg Q4W - Extended Treatment Period</title>
            <description>Participants who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q4W during the Extension Period.
Participants who remained on placebo at the completion of the double blind treatment period received the first dose of ixekizumab (160 mg starting dose) at Week 24.
Participants who were IRs at Week 16 and were re-randomized to ixekizumab at Week 16 received the first dose of ixekizumab (160 mg starting dose) at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ACR 70</title>
          <description>ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.</description>
          <population>All randomized participants. Non-responder Imputation (NRI) is applied for inadequate responders at week 16 and participants who discontinued on or prior to week 24.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6"/>
                    <measurement group_id="O2" value="28.8"/>
                    <measurement group_id="O3" value="15.2"/>
                    <measurement group_id="O4" value="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4"/>
                    <measurement group_id="O2" value="21.6"/>
                    <measurement group_id="O3" value="10.9"/>
                    <measurement group_id="O4" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline Up To 2.55 Years</time_frame>
      <desc>All randomized participants who received at least one dose of study drug. The gender specific events only occurring in male or female participants were adjusted accordingly.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ixekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment Period</title>
          <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 subcutaneous (SC) injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab every 2 Weeks (Q2W) given on Weeks 2, 4, 6, 8, 10, 12,14, 16, 18, 20, 22, and 24.</description>
        </group>
        <group group_id="E2">
          <title>Ixekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment Period</title>
          <description>Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14, 18, and 22.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (PBO) - Blinded Treatment Period</title>
          <description>Participants received placebo for ixekizumab as 2 SC injections followed by 1 SC injection Q2W given on Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24.</description>
        </group>
        <group group_id="E4">
          <title>Ixe 80 mg Q2W - Blinded Treatment Period IR</title>
          <description>Week 16 inadequate responders from the placebo treatment group who were re-randomized (1:1) to ixekizumab 80 mg Q2W and IR from ixekizumab 80 mg Q2W who continued on ixekizumab 80 mg Q2W. Patients receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20, 22, and 24.</description>
        </group>
        <group group_id="E5">
          <title>Ixe 80 mg Q4W - Blinded Treatment Period IR</title>
          <description>Week 16 inadequate responders from the placebo treatment group who were re-randomized (1:1) to ixekizumab 80 mg Q4W and IR from ixekizumab 80 mg Q4W who continued on ixekizumab 80 mg Q4W. Patients receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22.</description>
        </group>
        <group group_id="E6">
          <title>PBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IR</title>
          <description>Participants initially randomized to placebo treatment group in the double blind treatment period who were flagged as inadequate responders as week 16 were re-randomized to ixekizumab 80 mg Q2W for the remainder of the current period and following period.</description>
        </group>
        <group group_id="E7">
          <title>PBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IR</title>
          <description>Participants initially randomized to placebo treatment group in the double blind treatment period who were flagged as inadequate responders as week 16 were re-randomized to ixekizumab 80 mg Q4W for the remainder of the current period and following period.</description>
        </group>
        <group group_id="E8">
          <title>Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period</title>
          <description>Participants who were randomized to ixekizumab 80 mg Q2W at week 0 and continued on ixekizumab 80 mg Q2W during the Extension Period.</description>
        </group>
        <group group_id="E9">
          <title>Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period</title>
          <description>Participants who were randomized to ixekizumab 80 mg Q4W at week 0 and continued on ixekizumab 80 mg Q4W during the Extension Period.</description>
        </group>
        <group group_id="E10">
          <title>Placebo/ Ixe 80 mg Q2W - Extended Treatment Period</title>
          <description>Participants who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W during the Extension Period.
Participants who remained on placebo at the completion of the double blind treatment period received the first dose of ixekizumab (160 mg starting dose) at Week 24.
Participants who were IRs at Week 16 and were re-randomized to ixekizumab at Week 16 received the first dose of ixekizumab (160 mg starting dose) at Week 16.</description>
        </group>
        <group group_id="E11">
          <title>Placebo/ Ixe 80 mg Q4W - Extended Treatment Period</title>
          <description>Participants who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q4W during the Extension Period.
Participants who remained on placebo at the completion of the double blind treatment period received the first dose of ixekizumab (160 mg starting dose) at Week 24.
Participants who were IRs at Week 16 and were re-randomized to ixekizumab at Week 16 received the first dose of ixekizumab (160 mg starting dose) at Week 16.</description>
        </group>
        <group group_id="E12">
          <title>Ixe 80 mg Q2W - Post Treatment Follow-Up Period</title>
          <description>Participants who received ixekizumab 80 mg Q2W prior to entering the post-treatment follow-up period, who were either completed the study or discontinued the study early entered the post-treatment follow-up period (a 12-24 week period after their last scheduled treatment visit).</description>
        </group>
        <group group_id="E13">
          <title>Ixe 80 mg Q4W - Post Treatment Follow-Up Period</title>
          <description>Participants who received ixekizumab 80 mg Q4W prior to entering the post-treatment follow-up period, who were either completed the study or discontinued the study early entered the post-treatment follow-up period (a 12-24 week period after their last scheduled treatment visit).</description>
        </group>
        <group group_id="E14">
          <title>PBO - Post Treatment Follow-Up Period</title>
          <description>Participants who received PBO prior to entering the post-treatment follow-up period, who were either completed the study or discontinued the study early entered the post-treatment follow-up period (a 12-24 week period after their last scheduled treatment visit).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="107"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="111"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Latent tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa uteri cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="59" subjects_at_risk="107"/>
                <counts group_id="E9" subjects_affected="65" subjects_at_risk="111"/>
                <counts group_id="E10" subjects_affected="20" subjects_at_risk="46"/>
                <counts group_id="E11" subjects_affected="32" subjects_at_risk="46"/>
                <counts group_id="E12" subjects_affected="16" subjects_at_risk="142"/>
                <counts group_id="E13" subjects_affected="13" subjects_at_risk="145"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Entropion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="5" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="20" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="11" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="7" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="47" subjects_affected="15" subjects_at_risk="123"/>
                <counts group_id="E2" events="20" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="92" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E9" events="39" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E10" events="7" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="15" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="46" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="15" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="12" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E9" events="13" subjects_affected="11" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="4" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="122"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="26" subjects_affected="15" subjects_at_risk="107"/>
                <counts group_id="E9" events="32" subjects_affected="20" subjects_at_risk="111"/>
                <counts group_id="E10" events="11" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E11" events="6" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E12" events="4" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E13" events="5" subjects_affected="5" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="6" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="14" subjects_affected="10" subjects_at_risk="107"/>
                <counts group_id="E9" events="13" subjects_affected="11" subjects_at_risk="111"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="123"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="122"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="33" subjects_affected="20" subjects_at_risk="107"/>
                <counts group_id="E9" events="23" subjects_affected="15" subjects_at_risk="111"/>
                <counts group_id="E10" events="7" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E11" events="9" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="13" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E9" events="8" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="9" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E9" events="9" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="6" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E13" events="6" subjects_affected="6" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep terror</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

